Acquired company focused on radioligand therapies for the treatment of cancer.
Eli Lilly and Company announced that it has put in place a definitive agreement to acquire Point Biopharma, a radiopharmaceutical company with multiple clinical and preclinical stage radioligand therapies in development for the treatment of cancer. Under terms of the deal, Lilly will initiate a tender offer to acquire all outstanding shares for $12.50 per share and it has been approved by the boards of directors of both companies.
"Over the past few years, we have seen how well-designed radiopharmaceuticals can demonstrate meaningful results for patients with cancer and rapidly integrate into standards of care, yet the field remains in the early days of the impact it may ultimately deliver," said Jacob Van Naarden, President of Loxo@Lilly, Eli Lilly and Company’s Oncology Unit, in a compaby press release. "We are excited by the potential of this emerging modality and see the acquisition of Point as the beginning of our investment in developing multiple meaningful radioligand medicines for hard-to-treat cancers, as we have done in small molecule and biologic oncology drug discovery and development. We look forward to welcoming Point colleagues to Lilly and working together to build upon their achievements as we develop a pipeline of meaningful new radioligand treatments for patients."
Reference: Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies. Lilly. October 3, 2023. Accessed October 3, 2023. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-point-biopharma-expand-oncology-capabilities-next
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased Engagement
March 28th 2024The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.